The IL-33/ST2 Axis Protects the Hippocampus from LPS-Induced Inflammation and Damage by Modulating Microglial...

Area of Science:

• Neuroscience
• Immunology
• Pathology

Background:

• Systemic inflammation drives neurodegeneration, including amyloid accumulation and neuronal loss.
• The Interleukin-33 (IL-33)/Suppression of Tumorigenicity 2 (ST2) pathway is a key immune regulator in the brain.
• The specific role of IL-33/ST2 in hippocampal pathology during endotoxemia remains unclear.

Purpose of the Study:

• To investigate the role of the IL-33/ST2 axis in neurodegenerative processes caused by systemic inflammation.
• To determine the effects of IL-33/ST2 signaling on hippocampal pathology following lipopolysaccharide (LPS) challenge.

Main Methods:

• BALB/c wild-type (WT) and ST2-deficient (ST2-/-) mice were challenged with LPS.
• Exogenous IL-33 was administered to a subgroup of WT mice.
• Immunohistochemistry, TUNEL assay, flow cytometry, and RT-PCR were used to assess neuroinflammation, apoptosis, microglial phenotype, and cytokine expression.

Main Results:

• LPS induced demyelination and amyloid deposition, most severe in ST2-/- mice, with increased IL-1β and apoptosis.
• Exogenous IL-33 treatment in WT mice showed neuroprotection, promoting phagocytic microglia and upregulating IL-10.
• IL-33 treatment preserved myelin, reduced amyloid load, and prevented hippocampal apoptosis.

Conclusions:

• The IL-33/ST2 axis is crucial for defense against LPS-induced neuroinflammation and neurodegeneration.
• IL-33 promotes a regulatory microglial state, balancing IL-10/IL-1β ratio to prevent neuronal damage.
• The IL-33/ST2 pathway holds potential for treating amyloid-related pathologies.